Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping

Contributed by: Business Wire

Logo

Tags

Biotechnology

Pharmaceutical

Health

Other Health

Restylane Shaype, Facial Shaping, Injectable

More Like This

Galderma Announces Regulatory Approval for Restylane® SHAYPE™, a New Hyaluronic Acid Injectable Designed for Augmenting the Chin Region

AMWC Dubai: Galderma Demonstrates Injectable Aesthetics Leadership Through Updates on Its Scientific Innovations and Community Education

IMCAS 2025: Galderma’s Broad Presence and New Data on Recently Launched Products Restylane® SHAYPE™ and Relfydess® Reaffirm Its Category Leadership

Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics

IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio

Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty

AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio

ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline